DOUBLING DOLUTEGRAVIR DOSAGE REDUCES HIV PERSISTENCE MARKERS IN ART-TREATED ADULTS
Background: Whether ongoing viral replication occurs in people living with HIV (PLWH) despite antiretroviral therapy (ART) and leads to low-level residual viremia is still debated. Here we report on a study, in which we intensified the ART regimen by doubling dolutegravir (DTG) dosage. We investigated the impact of this strategy on HIV blood and tissue…